非布司他治疗高尿酸血症与高同型半胱氨酸血症的疗效及安全性

详细信息    查看全文 | 推荐本文 |

英文篇名：Efficacy and Safety of Febuxostat in the Treatment of Hyperuricemia and Hyperhomocysteinemia 作者：谭树聪 英文作者：TAN Shu-cong;Department of Rheumatology and Immunology, Dongguan Kanghua Hospital; 关键词：非布司他 ; 高尿酸血症 ; 高同型半胱氨酸血症 ; 临床疗效 英文关键词：Febuxostat;;Hyperuricemia;;Hyperhomocysteinemia;;Clinical efficacy 中文刊名：HZZZ 英文刊名：China & Foreign Medical Treatment 机构：广东省东莞康华医院风湿免疫科; 出版日期：2019-05-21 出版单位：中外医疗 年：2019 期：v.38 基金：东莞市科技发展项目(2018507150591245) 语种：中文; 页：HZZZ201915037 页数：3 CN：15 ISSN：11-5625/R 分类号：118-120

摘要

目的探讨非布司他应用于治疗高尿酸血症与高同型半胱氨酸血症的疗效及安全性。方法随机选取该院于2017年6月—2018年11月间收治的80例高尿酸血症伴高同型半胱氨酸血症患者,并将其分为对照组(n=40)与观察组(n=40),对对照组应用降同型半胱氨酸药联合别嘌呤醇治疗,观察组则单纯用非布司他治疗。结果治疗后,观察组与对照组半胱氨酸水平分别为(10.12±3.42)μmol/L、(16.04±4.28)μmol/L,组间血浆同型半胱氨水平比较,差异有统计学意义(t=6.834,P<0.05);治疗后,观察组ET-1、NOS及UA值分别为(107.33±25.35)ng/L、(7.74±2.12)×10~3U/g protein、(324.65±47.28)μmol/L,对照组为(122.34±33.26)ng/L、(6.15±1.87)×10~3U/g protein、(351.26±50.33)μmol/L,观察组均优于对照组,差异有统计学意义(t=1.795,2.812,2.437,P<0.05);观察组不良反应发生率为5.00%(2/40),对照组不良反应发生率为7.50%(3/40),组间比较,差异无统计学意义(χ~2=0.533,P>0.05)。结论非布司他治疗高尿酸血症伴高同型半胱氨酸血症,具有在降低尿酸值的同时改善患者同型半胱氨酸水平,效果显著,值得在临床推广应用。
        Objective To investigate the efficacy and safety of febuxostat in the treatment of hyperuricemia and hyperhomocysteinemia. Methods Eighty patients with hyperuricemia and hyperhomocysteinemia who were admitted to our hospital from June 2017 to November 2018 were randomly selected and divided into control group(n=40) and the observation group(n=40), the same type of cysteine was combined with allopurinol in the control group, and the observation group was treated with febuxostat alone. Results After treatment, the cysteine levels in the observation group and the control group were(10.12±3.42) μmol/L and(16.04±4.28) μmol/L, respectively. The plasma homocysteine levels were compared between the groups. The difference was statistically significant( t=6.834, P<0.05); after treatment, the ET-1, NOS and UA values in the observation group were(107.33±25.35) ng/L,(7.74±2.12)×10~3 U/g protein,(324.65±47.28) μmol/L, respectively, the control group was(122.34±33.26) ng/L,(6.15±1.87)×10~3 U/g protein,(351.26±50.33) μmol/L, and the observation group was superior to the control group, the difference was statistically significant(t=1.795, 2.812, 2.437, P<0.05); the incidence of adverse reactions in the observation group was 5.00%(2/40), and the incidence of adverse reactions in the control group was 7.50%(3/40). The difference was not statistically significant(χ~2=0.533, P>0.05). Conclusion The treatment of hyperuricemia with hyperhomocysteinemia with febuxostat has the effect of improving the level of uric acid and improving the level of homocysteine in patients. The effect is significant and worthy of clinical application.

引文

[1]黄张亮.非布司他治疗痛风伴高尿酸血症的疗效及不良反应观察[J].健康研究,2018(5):560-562.
    [2]焦素敏,李绍梅.非布司他在慢性肾功能衰竭合并高尿酸血症老年患者中的有效性及安全性观察[J].广东医学,2018,39(14):2214-2217.
    [3]任广伟,李明明,杨洪娟,等.非布司他对维持性血液透析伴高尿酸血症患者血管内皮功能、氧化应激反应的影响及安全性评价[J].河北医药,2018,40(15):2251-2255.
    [4]任广伟,李明明,杨洪娟,等.非布司他对维持性血液透析伴高尿酸血症患者血清炎性因子水平和肝功能的影响[J].河北医药,2018,40(14):2171-2174,2178.
    [5]李杰.非布司他与别嘌呤治疗慢性肾脏病合并高尿酸血症临床效果比较[J].临床合理用药杂志,2018,11(16):84-86.
    [6]刘勇.甲钴胺治疗老年脑梗死伴高同型半胱氨酸血症患者卒中后抑郁的疗效[J].中国老年学杂志,2014,34(15):4176-4178.
    [7]李琼,张莉莉,李楠楠,等.马来酸依那普利叶酸片对老年高同型半胱氨酸血症并发脑梗死患者血管内皮功能的影响[J].中国老年学杂志,2017,37(15):3750-3751.
    [8]康玲伶,林萍萍,马征,等.急性脑梗死合并高同型半胱氨酸血症患者多靶点治疗的疗效观察[J].山东医药,2011,51(37):69-70.
    [9]周建华,林建群,朱勇冬,等.叶酸、甲钴胺治疗伴高同型半胱氨酸血症的急性脑梗死患者的效果观察[J].山东医药,2015,55(13):67-68.
    [10]陶小军,金星,陶沙,等.不同剂量非布司他对痛风伴高尿酸血症的效果及对内皮素-1水平的影响[J].中国全科医学,2014,17(2):170-172.